{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:35:37Z","timestamp":1773887737726,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0768-8","type":"journal-article","created":{"date-parts":[[2018,1,27]],"date-time":"2018-01-27T09:59:16Z","timestamp":1517047156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency"],"prefix":"10.1186","volume":"13","author":[{"given":"Maja","family":"Di Rocco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Pisciotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Madeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bertamino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,27]]},"reference":[{"key":"768_CR1","unstructured":"Hoffman EP, Barr ML, Giovanni MA, Murray MF Lysosomal Acid Lipase Deficiency. In: In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132017. 2015 Jul 30 [updated 2016 Sep 1]."},{"key":"768_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/gim.2015.108","volume":"18","author":"SA Jones","year":"2016","unstructured":"Jones SA, Valayannopoulos V, Schneider EES, Banikazemi M, Bialer M, Cederbaum S, Chan A, Dhawan A, Di Rocco M, Domm J, Enns GM, Finegold D, Gargus JJ, Guardamagna O, Hendriksz C, Mahmoud IG, Raiman J, Selim LA, Whitley CB, Zaki O, Quinn AG. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet Med. 2016;18:452\u20138.","journal-title":"Genet Med"},{"key":"768_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/MPG.0000000000000935","volume":"61","author":"BK Burton","year":"2015","unstructured":"Burton BK, Deegan PB, Enns Bari\u0107 I, Burrow TA, Camarena Grande C, Coker M, Consuelo-S\u00e1nchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG. Clinical features of Lysosomal Acid Lipase Deficiency - a longitudinal assessment of 48 children and adults. J Pediatr Gastroenterol Nutr. 2015;61:619\u201325.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"768_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ymgme.2009.02.007","volume":"97","author":"L Pisciotta","year":"2009","unstructured":"Pisciotta L, Fresa R, Bellocchio A, Pino E, Guido V, Cantafora A, Di Rocco M, Calandra S, Bertolini S. Cholesteryl Ester storage disease (CESD) due to novel mutations in the LIPA gene. Mol Genet Metab. 2009;97:143\u20138.","journal-title":"Mol Genet Metab"},{"key":"768_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","volume":"235","author":"\u017d Reiner","year":"2014","unstructured":"Reiner \u017d, Guardamagna O, Nair D, Soran H, Hovingh K, Bertolini S, Jones S, \u0106ori\u0107 M, Calandra S, Hamilton J, Eagleton T, Ros E. Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis. 2014;235:21\u201330.","journal-title":"Atherosclerosis"},{"key":"768_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/MPG.0b013e31828b36ac","volume":"56","author":"B Zhang","year":"2013","unstructured":"Zhang B, Porto AF. Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency. J Pediatric Gastroenterol Nutr. 2013;56:682\u20135.","journal-title":"J Pediatric Gastroenterol Nutr"},{"key":"768_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.atherosclerosis.2015.08.007","volume":"242","author":"F Zimetti","year":"2015","unstructured":"Zimetti F, Favari E, Cagliero P, Adorni MP, Ronda N, Bonardi R, Gomaraschi M, Calabresi L, Bernini F, Guardamagna O. Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease. Atherosclerosis. 2015;242:443\u20139.","journal-title":"Atherosclerosis"},{"key":"768_CR8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","volume":"373","author":"BK Burton","year":"2015","unstructured":"Burton BK, Balwani M, Feillet F, Bari\u0107 I, Burrow TA, Camarena Grande C, Coker M, Consuelo-S\u00e1nchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG, et al. A phase 3 trial of Sebelipase Alfa in Lysosomal acid lipase deficiency. N Engl J Med. 2015;373:1010\u201320.","journal-title":"N Engl J Med"},{"key":"768_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","volume":"44","author":"T Kosoglou","year":"2005","unstructured":"Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44:467\u201394.","journal-title":"Clin Pharmacokinet"},{"key":"768_CR10","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Goker-Alpan O, Watman N, El-Beshlawy A, Kishnani PS, Pedroso ML, Gaemers SJM, Tayag R, Peterschmitt MJ. Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385:2355\u201362.","journal-title":"Lancet"},{"key":"768_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.imlet.2017.07.004","volume":"188","author":"D Rigante","year":"2017","unstructured":"Rigante D, Cipolla C, Umberto Basile U, Gulli M, Savastano MC. Overview of immune abnormalities in lysosomal storage disorders. Immunol Lett. 2017;188:79\u201385.","journal-title":"Immunol Lett"},{"key":"768_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","volume":"92","author":"A Wree","year":"2014","unstructured":"Wree A, MD MG, Pe\u00f1a CA, Schlattjan M, Li H, Inzaugarat ME, Messer K, Canbay A, Hoffman HM, Feldstein AE. NLRP3 inflammasome activation is required for fibrosis development in nafld. J Mol Med. 2014;92:1069\u201382.","journal-title":"J Mol Med"},{"key":"768_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.bbrc.2013.12.096","volume":"443","author":"JC Chuang","year":"2014","unstructured":"Chuang JC, Lopez AM, Posey KS, Turley SD. Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease. Biochem Biophys Res Commun. 2014;443:1073\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"768_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bcp.2017.03.010","volume":"135","author":"JC Chuang","year":"2017","unstructured":"Chuang JC, Lopez AM, Turley SD. Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe. Biochem Pharmacol. 2017;135:116\u201325.","journal-title":"Biochem Pharmacol"},{"key":"768_CR15","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1080\/15548627.2017.1356977","volume":"21","author":"SH Kim","year":"2017","unstructured":"Kim SH, Kim G, Han DH, Lee M, Kim I, Kim B. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. Autophagy. 2017;21:1767\u201381.","journal-title":"Autophagy"},{"key":"768_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1476-511X-4-26","volume":"4","author":"VT Tadiboyina","year":"2005","unstructured":"Tadiboyina VT, Liu DM, Miskie BA, Wang J, Hegele RA. Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids Health Dis. 2005;4:26.","journal-title":"Lipids Health Dis"},{"key":"768_CR17","first-page":"2628","volume":"19","author":"SJ Cameron","year":"2015","unstructured":"Cameron SJ, Daimee U. Block RC a case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease. Eur Rev Med Pharmacol Sci. 2015;19:2628\u201333.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"768_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1872-034X.2010.00644.x","volume":"40","author":"M Yoneda","year":"2010","unstructured":"Yoneda M, Fujita K, Nozaki YEndo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res. 2010;40:566\u201373.","journal-title":"Hepatol Res"},{"key":"768_CR19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2337\/dc09-1765","volume":"33","author":"DC Chan","year":"2010","unstructured":"Chan DC, Watts GF, Gan Y, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 2010;33:1134\u20139.","journal-title":"Diabetes Care"},{"key":"768_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","volume":"57","author":"Y Takeshita","year":"2014","unstructured":"Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, Misu H, Ota T, Nakamura M, Yamada K, Sunagozaka H, Arai K, Yamashita T, Mizukoshi E, Kaneko S. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014;57:878\u201390.","journal-title":"Diabetologia"},{"key":"768_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00535-010-0291-8","volume":"46","author":"H Park","year":"2011","unstructured":"Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101\u20137.","journal-title":"J Gastroenterol"},{"key":"768_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1476-511X-9-29","volume":"9","author":"M Enjoji","year":"2010","unstructured":"Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, Matsunaga K, Nakashima M, Nakamuta M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis. 2010;9:29.","journal-title":"Lipids Health Dis"},{"key":"768_CR23","first-page":"1383","volume":"108","author":"T Shiwa","year":"2011","unstructured":"Shiwa T, Kawanami Y, Yokoyama T, Moritani A, Hashimoto M, Gotoh T. The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD). Nihon Shokakibyo Gakkai Zasshi. 2011;108:1383\u201392.","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"768_CR24","doi-asserted-by":"publisher","unstructured":"Nakade Y, Murotani K, Inoue T, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Ito K, Fukuzawa Y, Yoneda M. Ezetimibe for the treatment of non-alcoholic fatty liver disease: a meta-analysis. \n                    Hepatol Res\n                    \n                  . 2017; \n                    https:\/\/doi.org\/10.1111\/hepr.12887\n                    \n                  .","DOI":"10.1111\/hepr.12887"},{"key":"768_CR25","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","volume":"58","author":"DL Bernstein","year":"2013","unstructured":"Bernstein DL, Hulkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with underdiagnosed disease. J Hepatol. 2013;58:1230\u201343.","journal-title":"J Hepatol"},{"key":"768_CR26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.jacl.2016.07.005","volume":"10","author":"RC Block","year":"2016","unstructured":"Block RC, Razani B. Options to consider when treating lysosomal acid lipase deficiency. J Clin Lipidol. 2016;10:1280\u20131.","journal-title":"J Clin Lipidol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0768-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T00:12:42Z","timestamp":1548547962000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0768-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0768-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,27]]},"assertion":[{"value":"10 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The drug was not used in an interventional trial, but it was used with the usual indication of \u201chypercholesterolemia\u201d in adult patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients gave written consensus for genetic molecular analysis and for publication of genetic and clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"24"}}